Join our daily newsletter At The Bell to receive exclusive market insights
- Lumos Diagnostics (LDX) receives US$250,000 (A$352,600) in initial orders for its rapid covid antigen test in Canada
- The test received authorisation to be sold in Canada last month
- Initial orders were made by multiple distributors with orders expect to be shipped this month
- The company says it expects ongoing demand and commercial momentum for the product in the next year
- Shares closed 3.45 per cent lower today at 70 cents
Lumos Diagnostics (LDX) has received US$250,000 (A$352,600) worth of initial orders for its rapid covid antigen test in Canada.
CoviDx SARS-CoV-2 is a rapid antigen test which received authorisation to be sold in Canada in November. The test gives qualified healthcare providers results within 15 to 20 minutes as to whether a patient has covid-19.
The initial orders were generated by multiple distributors as well as an order from a large healthcare provider. These orders are expected to be shipped within this month.
Managing Director Rob Sambursky said he expects ongoing demand and commercial momentum for the product to grow in Canada next year.
“Routine testing for SARS-CoV-2 using rapid antigen tests is a key element of Canada’s strategy for managing the pandemic. In view of this, the Canadian Government has committed to a significant investment to ensure rapid SARS-CoV-2 tests are readily available for healthcare providers, schools, workplaces and individuals,” he said.
“We are pleased with these initial commercial orders for CoviDx so soon after receiving our Interim Order authorisation from Health Canada. Based on feedback from our Canadian distributors and healthcare organisations, we expect the demand and commercial momentum for CoviDx in Canada to continue to grow into 2022.”
Shares closed 3.45 per cent lower today at 70 cents.
